# Deccan Health C (NSE: DECCAN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DECCAN · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹32 Cr, it ranks 3335th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 2.3% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹21 Cr (+1.1% year on year) and net profit ₹0 Cr (+175.0%), on a consolidated basis. Promoters held 19.46% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹32 Cr |
| ROE | 2.3% (FY26) |
| ROCE | 3.2% (FY26) |
| Debt to equity | 0.04 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹21 Cr | +1.1% | ₹0 Cr | +175.0% | ₹0.14 |
| Q3 FY26 | ₹17 Cr | −14.9% | ₹1 Cr | +614.3% | ₹0.41 |
| Q2 FY26 | ₹21 Cr | +13.7% | ₹1 Cr | +71.7% | ₹0.37 |
| Q1 FY26 | ₹22 Cr | +67.9% | ₹0 Cr | −33.3% | ₹0.10 |
| Q4 FY25 | ₹21 Cr | +29.9% | ₹0 Cr | −7.7% | ₹0.05 |
| Q3 FY25 | ₹20 Cr | +33.2% | ₹0 Cr | −73.6% | ₹0.07 |
| Q2 FY25 | ₹19 Cr | +9.5% | ₹1 Cr | −1.9% | ₹0.26 |
| Q1 FY25 | ₹13 Cr | +17.3% | ₹0 Cr | +20.0% | ₹0.18 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹75 Cr | ₹1 Cr |
| FY24 | ₹60 Cr | ₹1 Cr |
| FY23 | ₹45 Cr | ₹0 Cr |
| FY22 | ₹33 Cr | ₹0 Cr |
| FY21 | ₹34 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 19.46%
- Domestic institutions: 5.68%
- Non-institutions: 74.86%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [JFL Life Scienc](https://app.pivotnow.in/stock/JFLLIFE) | ₹10.30 | ₹34 Cr | 0.2 | — |
| [Chandra Bhagat](https://app.pivotnow.in/stock/CBPL) | — | ₹33 Cr | — | — |
| [Sharma East Ind](https://app.pivotnow.in/stock/SHARMEH) | — | ₹33 Cr | — | — |
| [Medi-Caps](https://app.pivotnow.in/stock/MEDICAPQ) | ₹25.50 | ₹32 Cr | — | — |
| [KK Shah Hospita](https://app.pivotnow.in/stock/KKSHL) | — | ₹30 Cr | — | — |
| [Panjon](https://app.pivotnow.in/stock/PANJON) | — | ₹30 Cr | — | — |

## Questions and answers

### What is the market cap of Deccan Health C?

Deccan Health C's market capitalisation is ₹32 Cr (₹32 Cr) at the 22 Oct 2026 close, ranking 3335th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Deccan Health C?

Return on equity was 2.3% in FY26 and return on capital employed was 3.2% in FY26 (consolidated figures).

### Is Deccan Health C a debt-free company?

Deccan Health C is close to debt-free: its debt-to-equity ratio was 0.04 in FY26.

### What were Deccan Health C's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Deccan Health C reported revenue of ₹21 Cr, +1.1% year on year, and net profit of ₹0 Cr, +175.0% year on year.

### What is the shareholding pattern of Deccan Health C?

As of 30 Jun 2026: promoters 19.46%, domestic institutions 5.68%, non-institutions 74.86%.

### Who are Deccan Health C's competitors?

The listed Pharma & Healthcare companies closest to Deccan Health C by market cap are JFL Life Scienc, Chandra Bhagat, Sharma East Ind, Medi-Caps, KK Shah Hospita and Panjon.

### Is Deccan Health C a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Deccan Health C's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DECCAN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.